-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Blood clotting may be the root cause of "long-term new crown" symptoms
Blood clotting may be the root cause of "long-term new crown" symptomsSource: Journal of Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis Source: Journal of Thrombosis and HaemostasisRecently, a study published in the Journal of Thrombosis and Haemostasis showed that blood clotting may be the root cause of some patients with new coronary pneumonia that have "long-term symptoms" that last for weeks or months after the infection disappears
Researchers examined 50 "long-term new crown" patients and found that compared with healthy controls, the blood coagulation markers of "long-term new crown" patients were significantly higher
Researchers pointed out that the hypercoagulable state of blood is directly related to other symptoms of "long-term new crown", such as decreased physical fitness and fatigue
New research finds ideal target for live attenuated coronavirus vaccine
New research finds ideal target for live attenuated coronavirus vaccineSource: Emerging Microbes & Infections
Source: Emerging Microbes & Infections Source: Emerging Microbes & InfectionsRecently, a study published in "Emerging Microbes & Infections" proposed that N7-methyltransferase is an ideal target for the development of a live attenuated coronavirus vaccine, and the target and mechanism are There is extensive conservation in the virus genus
The research team selected murine hepatitis virus (MHV, a highly pathogenic model coronavirus, which belongs to the β-coronavirus subgenus with SARS-CoV, MERS-CoV, and SARS-CoV-2) as the research model, using reverse genetics The scientific system has developed two mutant viruses rMHVD330A and Y414A with mutations in the key active site of N7-methyltransferase, and identified the pathogenicity and immunogenicity of these two recombinant attenuated viruses
The researchers pointed out that the replication-stable N7-methyltransferase attenuation strategy also has application value in the large-scale safe production of inactivated vaccines
New method can reduce the time and cost of new coronavirus testing
New method can reduce the time and cost of new coronavirus testingSource: IScience
Source: IScience Source: IScienceRecently, in a work published in IScience, researchers have developed a new sample preparation method for the detection of new coronaviruses.
After collecting patient samples, the research team used the chelating agent Chelex 100 resin to preserve the new coronavirus RNA in the sample, and stored them in the virus transport medium or the newly developed chelating resin-buffer in the NIH symptom testing facility
The mRNA vaccine still has a protective effect on 6 variants after half a year of vaccination
The mRNA vaccine still has a protective effect on 6 variants after half a year of vaccinationSource: Science
Source: Science Source: ScienceOn August 12, a study published in Science showed that after two doses of Moderna mRNA-1273 vaccine, after six months, the induced antibodies mutated against six new coronaviruses including the Delta variant The strain still has binding capacity and functionality
Volunteers received 2 doses of mRNA-1273 vaccine at 28 days intervals as required, and provided blood samples at 4 weeks after the first injection, two weeks after the second injection, 3 months, and 6 months for the researchers to evaluate.
For the delta variant, 96% of the test samples showed a neutralization reaction, but for the beta variant, only half of the test samples had a neutralization reaction, and the antibody titers against the beta variant were the lowest in the serum
Vaccine protection against delta variants has decreased
Vaccine protection against delta variants has decreasedSource: NEJM
Source: NEJM Source: NEJMOn August 12, a study published in the New England Journal of Medicine (NEJM) published real-world vaccine protection efficiency data in the UK.
The protection efficiency of two doses of BNT162b2 vaccine against the delta variant strain was 88.
The research team said that despite the decline in protection efficiency, mRNA vaccines and adenovirus vaccines still have better protection against delta mutant strains
Germany promotes vaccination of young people against the new crown
Germany promotes vaccination of young people against the new crownOn August 16, the German Permanent Vaccination Committee (STIKO) changed its previous cautious attitude after months of consideration and evaluation, recommending that all teenagers between the ages of 12 and 17 be vaccinated against the new crown
According to data from the Robert Koch Institute (RKI), compared with the overall vaccination rate of more than 57.
Vaccination with inactivated vaccine is associated with facial paralysis
Vaccination with inactivated vaccine is associated with facial paralysisSource: the Lancet Infectious Diseases
Source: the Lancet Infectious Diseases Source: the Lancet Infectious DiseasesOn August 16, a study published in The Lancet Infectious Diseases compared the proportion of Bell's palsy (facial paralysis) caused by vaccination with different vaccines, including the most widely used inactivated virus vaccine in China
.
The researchers collected data on the occurrence of facial paralysis within 42 days after vaccination of BNT162b2 and CoronaVac, and the results showed that vaccination of CoronaVac was associated with an increased risk of occurrence of facial paralysis, while vaccination of BNT162b2 was not
.
However, the benefits of vaccination are still far higher than the risk of new coronavirus infection if not vaccinated
.
The first broad-spectrum humanized genetically engineered monoclonal antibody against the new coronavirus shows good safety
The first broad-spectrum humanized genetically engineered monoclonal antibody against the new coronavirus shows good safetySource: Nature Communications
Source: Nature Communications Source: Nature CommunicationsOn August 17, a study published in Nature Communications reported for the first time a blocking antibody targeting multiple coronavirus invasion receptors ACE2; this antibody can effectively prevent and treat new types of coronaviruses.
Coronavirus and its mutant strains infect host cells and model animals, and show good safety in non-human primates
.
The researchers first obtained a blocking monoclonal antibody h11B11 that targets the human ACE2 receptor through rapid screening and humanization of the antibody; after a variety of coronaviruses’ pseudovirus and true virus neutralization evaluations, the antibody h11B11 was confirmed It has good inhibitory activity against SARS-CoV, SARS-CoV-2 and its mutant viruses; the combination of this antibody and the new crown therapeutic antibody CB6 developed by the Institute of Microbiology in the early stage can synergistically increase the neutralizing activity
.
Uneven distribution of vaccines may lead to new variants
Uneven distribution of vaccines may lead to new variantsSource: Science
Source: Science Source: ScienceOn August 17, a collaborative study published in Science found that uneven distribution of vaccines may increase the number of global new crown cases and cause the emergence of new variants, emphasizing the importance of fair and rapid global vaccine distribution.
Importance and urgency
.
Researchers predicted the incidence of new crown cases in two model areas of high vaccine penetration rate and low penetration rate area under a series of vaccine dosage systems, vaccination rates, and immune response-related assumptions
.
The prediction results show that increasing vaccine sharing reduces the number of cases in low-prevalence areas, and if the number of cases in low-prevalence areas continues to rise, it will increase the potential for virus evolution
.
SARS survivors vaccinated with the new crown vaccine will produce higher levels of neutralizing antibodies in their bodies
SARS survivors vaccinated with the new crown vaccine will produce higher levels of neutralizing antibodies in their bodiesSource: NEJM
Source: NEJM Source: NEJMOn August 18, in a work published in the New England Journal of Medicine (NEJM), researchers tested SARS survivors who were vaccinated with the new crown vaccine, SARS survivors who had not been vaccinated with the new crown vaccine, and the new crown pneumonia vaccinated with the new crown vaccine.
Recovered people and other five groups of people conducted research and found that SARS recovered people who received the new crown vaccine would produce higher levels of neutralizing antibodies against the SARS virus and the new crown virus
.
In addition, the antibodies in these survivors have neutralizing effects against several recent coronavirus variants, five of the same subgenus coronaviruses from bats and pangolins
.
The researchers pointed out that the new crown vaccine may awaken the immune system's "memory" of the domain shared by the SARS virus and other viruses, thereby activating the immune response
.
The study shows that it is possible to develop a broad-spectrum vaccine that is effective against Sarbecovirus and other coronaviruses
.
Leave a message here